Overview

Full Product Details

9780198842255

Table of Contents

Reviews

Author Information

Phil Ambery is a Global Clinical Head in AstraZeneca, Gothenburg, Sweden. He leads clinical development of drug projects from phase 2 to launch in the cardiovascular, renal, metabolic and liver space. Over more than 20 years in Pharma he's led more than 10 clinical projects, first in GSK and now in AZ. He's passionate about teaching and education in pharma medicine and in the NHS, is a GMC associate and dual fellow of the college of physicians and faculty of pharmaceutical medicine. Adrian Kilcoyne has led drug development programmes across a range of projects in the past 20 years. He brings a wealth of experience as an editor of the handbook, having worked across diverse therapy areas and both small and large pharma. Adrian holds an MBA as well as a range of postgraduate medical qualifications. Daniel O'Connor is medically and PhD qualified and currently the Director Regulatory and Early Access Policy at The Association of the British Pharmaceutical Industry (ABPI). He joined the ABPI after 16 years at the Medicines and Healthcare products Regulatory Agency (MHRA). At the MHRA he was Deputy Director of the Innovation Accelerator and Regulatory Science. Dan has special interests in drug development, rare diseases, regulatory science, early access and health innovation. He previously held a Clinical Lecturer post at UCL and completed higher medical training in Pharmaceutical Medicine.

Tab Content 6

Countries Available